Malignancies developing in obese patients with psoriasis while on antitumour necrosis factor-α therapies: a case series

Br J Dermatol. 2012 Oct;167(4):937-8. doi: 10.1111/j.1365-2133.2012.10947.x. Epub 2012 Jun 11.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Psoriatic / drug therapy*
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / therapeutic use
  • Male
  • Middle Aged
  • Neoplasms / chemically induced*
  • Obesity / complications*
  • Psoriasis
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Tumor Necrosis Factor-alpha / adverse effects
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Adalimumab
  • Etanercept